Gts Securities LLC Madrigal Pharmaceuticals, Inc. Call Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	BUY	$212.22 - $292.96 $509,328 - $703,104	2,400 Added 9.68%	27,200 $5.77 Million
Q2 2024 Aug 14, 2024	SELL	$193.33 - $291.99 $3 Million - $4.53 Million	-15,500 Reduced 38.46%	24,800 $6.95 Million
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $1.29 Million - $2.12 Million	7,500 Added 22.87%	40,300 $10.8 Million
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $1.69 Million - $3.32 Million	14,000 Added 74.47%	32,800 $7.59 Million
Q3 2023 Nov 15, 2023	BUY	$146.04 - $225.78 $2.75 Million - $4.24 Million	18,800 New	18,800 $2.75 Million

297

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.34B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.